TO EVALUATE THE EFFECT OF INTRAVITREAL INJECTION OF TRIAMCINOLONE ACETONIDE IN RECALCITRANT MACULAR DISORDERS.


Amit K Jain, Seema Jain, Dadan Ji Pandey, Rajkumar Sharma

Abstract


Objectives: Recalcitrant macular disorders are those retinal conditions which, though treated by various medical and surgical modalities, but showed
no improvement in symptoms or visual acuity or both. The present study was carried out to evaluate the efficacy of intravitreal triamcinolone
acetonide (TA) injection in patients with these recalcitrant macular disorders.
Methods: This prospective and interventional study included 40 patients (40 eyes) having recalcitrant macular disorders. Complete ophthalmic
examination such as measurement of intraocular pressure (IOP), visual acuity (log minimal angle of resolution [MAR] units), fundus photography with
fluorescein angiography were carried out before and after intravitreal injection of TA. The patients received an intravitreal injection of TA (10 mg) for
diabetic macular edema (n=14), age-related macular degeneration (n=13), pars plana cystoid macular edema (CME) (n=5), vascular diseases (n=3),
central chorioretinopathy (n=3), and idiopathic CME (n=2). The follow-up was done on day 1, day 7, 1 month, 2 month and 4-month intervals.
Results: The mean visual acuity at 2 months (1.12±0.45 log MAR units), and 4 months (1.08±0.46 log MAR unit) after the injection were significantly
better than baseline measurements (1.32±0.3 log MAR units). The mean baseline IOP was 12.5±2.9 mmHg. The IOP significantly increased after the
injection at day 1 and day 7; however, the change in IOP at 1 month, 2 months, and 4 months was not statistically significant.
Conclusion: The results indicate that intravitreal injection of TA in patients with recalcitrant macular disorders caused significant improvement of
visual acuity in 10 mg dose.
Keywords: Intravitreal triamcinolone acetonide, Macular edema, Visual acuity, Intraocular pressure.


| PDF |

References


Gopal L, Sharma T. Use of intravitreal injection of triamcinolone

acetonide in the treatment of age-related macular degeneration. Indian

J Ophthalmol 2007;55(6):431-5.

Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the

treatment of retinal diseases. ScientificWorldJournal 2014;2014:989501.

Tewari HK, Sony P, Chawla R, Garg SP, Venkatesh P. Prospective

evaluation of intravitreal triamcinolone acetonide injection in macular

edema associated with retinal vascular disorders. Eur J Ophthalmol

;15(5):619-26.

Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular

oedema treated by intravitreal triamcinolone acetonide. A comparative

nonrandomized study. Br J Ophthalmol 2005;89:321-6.

Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal

triamcinolone acetonide for macular oedema due to central retinal vein

occlusion. Br J Ophthalmol 2002;86(2):247-8.

Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone

acetonide for the treatment of central retinal vein occlusion in young

patients. Retina 2004;24(2):324-7.

Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as

adjunctive treatment of diabetic macular edema. Am J Ophthalmol

;132(3):425-7.

Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA,

Asian J Pharm Clin Res, Vol 8, Issue 6, 2015, 157-160

Jain et al

Reichel E, et al. Intravitreal triamcinolone for refractory diabetic

macular edema. Ophthalmology 2002;109(5):920-7.

Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of

triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol

;121(1):57-61.

Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF,

Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic

diffuse macular edema: Preliminary results of a prospective controlled

trial. Ophthalmology 2004;111(2):218-24.

Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular

degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J

Ophthalmol 1995;23(4):293-8.

Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone

acetonide in exudative age-related macular degeneration. Retina

;20(3):244-50.

Jonas JB, Kreissig I, Degenring R. Repeated intravitreal injections of

triamcinolone acetonide as treatment of progressive exudative agerelated

macular

degeneration.

Graefes

Arch

Clin Exp Ophthalmol

;240(10):873-4.

Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al.

A randomized clinical trial of a single dose of intravitreal triamcinolone

acetonide for neovascular age-related macular degeneration: One-year

results. Arch Ophthalmol 2003;121(5):667-73.

Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal

reinjection of triamcinolone for exudative age-related macular

degeneration. Arch Ophthalmol 2004;122(2):218-22.

Jonas JB, Söfker A. Intravitreal triamcinolone acetonide for cataract

surgery with iris neovascularization. J Cataract Refract Surg

;28(11):2040-1.

Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of

neovascular iris vessels by intravitreal injection of crystalline cortisone.

J Glaucoma 2001;10(4):284-7.

Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline

cortisone as treatment of pre-phthisical ocular hypotony. Graefes Arch

Clin Exp Ophthalmol 2001;239(6):464-5.

Rodriguez ML, Juarez CP, Luna JD. Intravitreal triamcinolone acetonide

injection in blind painful eyes. Intraocular steroids as a treatment for

blind painful red eyes. Eur J Ophthalmol 2003;13(3):292-7.

McCuen BW 2

, Bessler M, Tano Y, Chandler D, Machemer R. The

lack of toxicity of intravitreally administered triamcinolone acetonide.

Am J Ophthalmol 1981;91(6):785-8.

nd

Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al.

Safety of an intravitreal injection of triamcinolone: Results from a

randomized clinical trial. Arch Ophthalmol 2004;122(3):336-40.

Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated

intraocular pressure. Aust N Z J Ophthalmol 1999;27(6):431-2.

Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP,

et al. Acute endophthalmitis following intravitreal triamcinolone

acetonide injection. Am J Ophthalmol 2003;136(5):791-6.

Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous

injection: A comprehensive review. Retina 2004;24(5):676-98.

Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS.

Safety and efficacy of intravitreal triamcinolone acetonide for uveitic

macular edema. Ocul Immunol Inflamm 2005;13(2-3):205-12.

Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA.

Intraocular pressure elevation after intravitreal triamcinolone acetonide

injection. Ophthalmology 2005;112(4):593-8.

Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular

inflammation and associated macular edema. Clin Ophthalmol

;3:41-7.

Klein R, Klein BE, Moss SE. Visual impairment in diabetes.

Ophthalmology 1984;91(1):1-9.

Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant

macular edema after intravitreal bevacizumab is responsive to an

intravitreal dexamethasone implant in retinal vein occlusion. Retina

;33(6):1227-31.

Barnes PJ. Anti-inflammatory actions of glucocorticoids: Molecular

mechanisms. Clin Sci (Lond) 1998;94(6):557-72.

Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R.

Intravitreal triamcinolone acetonide for exudative age related macular

degeneration. Br J Ophthalmol 2003;87(4):462-8.

Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E

Jr. Treatment with intravitreal steroid reduces blood-retinal barrier

breakdown due to retinal photocoagulation. Arch Ophthalmol

;110(8):1155-9.

Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E,

Roth M. Corticosteroids inhibit the expression of the vascular

endothelial growth factor gene in human vascular smooth muscle cells.

Eur J Pharmacol 1998;341(2-3):309-15.

Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM.

Triamcinolone acetonide modulates permeability and intercellular

adhesion molecule-1 (ICAM-1) expression of the ECV304 cell

line: Implications for macular degeneration. Clin Exp Immunol

;121(3):458-65.

Floman N, Zor U. Mechanism of steroid action in ocular inflammation:

Inhibition of prostaglandin production. Invest Ophthalmol Vis Sci

;16(1):69-73.

Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin

synthesis by glucocorticoids in human endothelial cells. Endocrinology

;119(1):62-9.

Couch SM, Bakri SJ. Use of triamcinolone during vitrectomy surgery to

visualize membranes and vitreous. Clin Ophthalmol 2008;2(4):891-6.

Vedantham V, Kim R. Intravitreal injection of triamcinolone acetonide

for diabetic macular edema: Principles and practice. Indian J

Ophthalmol 2006;54(2):133-7.

Pickrell A, Harris A, Ngo S, Amireskandari A, Stewart E, Siesky B.

Delivery of intraocular triamcinolone acetonide in the treatment of

macular edema. Pharmaceutics 2012;4(1):230-42.

Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline

cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J

Ophthalmol 2000;84(9):1064-7.

Jonas JB, Kreissig I, Kamppeter B, Degenring RF. Intravitreal

triamcinolone acetonide for the treatment of intraocular edematous and

neovascular diseases. Ophthalmologe 2004;101(2):113-20.

Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal

triamcinolone for treatment of complicated proliferative diabetic

retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol

;40(5):598-604.

Choi YJ, Oh IK, Oh JR, Huh K. Intravitreal versus posterior subtenon

injection of triamcinolone acetonide for diabetic macular edema.

Korean J Ophthalmol 2006;20(4):205-9.

Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA.

Inter-eye difference in exudative age-related macular degeneration with

minimally classic or occult subfoveal neovascularization after unilateral

intravitreal injection of triamcinolone acetonide. Am J Ophthalmol

;139(6):1073-9.

Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal

triamcinolone acetonide and intraocular pressure. Am J Ophthalmol

;138(5):740-3.

Park HY, Yi K, Kim HK. Intraocular pressure elevation after

intravitreal triamcinolone acetonide injection. Korean J Ophthalmol

;19(2):122-7.




About this article

Title

TO EVALUATE THE EFFECT OF INTRAVITREAL INJECTION OF TRIAMCINOLONE ACETONIDE IN RECALCITRANT MACULAR DISORDERS.

Date

01-11-2015

Additional Links

Manuscript Submission

Journal

Asian Journal of Pharmaceutical and Clinical Research
Vol 8 Issue 6 (November - December) 2015 Page: 157-160

Print ISSN

0974-2441

Online ISSN

2455-3891

Statistics

71 Views | 133 Downloads

Authors & Affiliations

Amit K Jain
India

Seema Jain

Dadan Ji Pandey

Rajkumar Sharma


Article Tools


Email this article (Login required)
Email the author (Login required)

Refbacks

  • There are currently no refbacks.